Live Nasdaq Composite: Tech Rises on Chip Stock Tailwinds but Software Sinks

Health and Healthcare

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

1270 Articles

Douglas A. McIntyre | Nov 12, 2007 at 6:45 AM EST

As Doctors Renew Interest In Stents, Boston Scientific (BSX) May Get A Break

Several studies which showed that stents could cause blood clotting in the heart have done significant damage to the revenue…

Douglas A. McIntyre | Nov 12, 2007 at 4:24 AM EST

Media Digest 11/12/2007 Reuters, WSJ, NYTimes, FT, Barron’s

According to Reuters, BHP Billiton (BHP) will not sell its petroleum division, as had been rumored, to finance a bid…

Douglas A. McIntyre | Nov 8, 2007 at 12:08 PM EST

Defensive Stocks Show Rotation Out of Tech (PEP, KO, BUD, TAP, KFT, CAG, CPB, HRL, MCD, MO, VGR, RAI, PG, CL, MRK, JNJ, NVO)

The markets haven’t fallen apart after yesterday’s 360 point dive on the DJIA, but we are still trading a tad…

Douglas A. McIntyre | Nov 5, 2007 at 5:54 AM EST

Boston Scientific (BSX): Saving Itself Through Auctioning Off Pieces

Boston Scientific (BSX) did it shareholders a terrible disservice buy buying Guidant in a bidding war with Johnson & Johnson.…

Douglas A. McIntyre | Nov 1, 2007 at 12:30 PM EDT

Defensive Stocks Show No Panic Rotation (PEP, KO, BUD, TAP, KFT, CAG, CPB, HRL, MCD, MO, VGR, RAI, PG, CL, MRK, JNJ, NVO)

With the markets down so much today on the financial stock fallout after the Citi downgrade/concern and with oil stocks…

Douglas A. McIntyre | Oct 21, 2007 at 10:17 AM EDT

For Boston Scientific And JNJ, The Stent Stats Get Worse

"William O’Neill, dean of clinical affairs at University of Miami’sMiller School of Medicine, says stent-patient traffic is beginning topick up…

Douglas A. McIntyre | Oct 16, 2007 at 9:07 AM EDT

Interpreting Amgen Sales From J&J’s PROCRIT (AMGN, JNJ)

Shares of Amgen Inc. (NASDAQ:AMGN) are under bit of pressure this morning, although not from any direct news from the…

Douglas A. McIntyre | Oct 16, 2007 at 7:03 AM EDT

Johnson & Johnson’s (JNJ) Good Quarter

Johnson & Johnson (JNJ) announced third-quarter sales of $15.0 billion, an increase of 12.7% as compared to the third quarter…

Douglas A. McIntyre | Oct 11, 2007 at 5:57 AM EDT

As Stent Business Falls Apart, Field Gets More Crowded

Medtronic (MDT) got the FDA to approve its new drug-coated stent called the Endeavor. The agency did have some concerns…

Douglas A. McIntyre | Oct 6, 2007 at 3:10 PM EDT

Medtronic (MDT): The Stent Business Gets Worse

Medtronic (MDT) has decided to get into the stent business, making the little mesh tubes that keep arteries open. It…

Douglas A. McIntyre | Oct 4, 2007 at 5:37 AM EDT

For Boston Scientific (BSX) Stent News Gets More Complex

Stent sales for Boston Scientific (BSX) and Johnson & Johnson (JNJ) have taken a big drop since research began to…

Douglas A. McIntyre | Sep 14, 2007 at 3:22 AM EDT

Media Digest 9/14/2007 Reuters, WSJ, NYTimes, FT, Barron’s

According to Reuters, Intel (INTC) received antitrust charges from a branch of the South Korean government. Reuters writes that Campbell…

Douglas A. McIntyre | Sep 13, 2007 at 7:32 AM EDT

ISIS Scores On J&J Collaboration & Milestones (ISIS, JNJ)

ISIS Pharmaceuticals Inc. (NASDAQ:ISIS) is trading up pre-market on new that it entered a broad collaboration with Ortho-McNeil, a Johnson…

Douglas A. McIntyre | Sep 12, 2007 at 7:25 AM EDT

Amgen Set To Run (AMGN, JNJ, BIIB)

Amgen Inc. (NASDAQ:AMGN) is seeing shares trade up another 2% pre-market after yesterday’s decision where an FDA panel rejected a…

Douglas A. McIntyre | Sep 7, 2007 at 3:32 PM EDT

Defensive Stock Picks Better Than The Market (September 7, 2007)

We are frequently asked about how certain basket picks perform compared to the overall market. It has been years since…

1 … 81 82 83 84 85

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

As Doctors Renew Interest In Stents, Boston Scientific (BSX) May Get A Break

Media Digest 11/12/2007 Reuters, WSJ, NYTimes, FT, Barron’s

Defensive Stocks Show Rotation Out of Tech (PEP, KO, BUD, TAP, KFT, CAG, CPB, HRL, MCD, MO, VGR, RAI, PG, CL, MRK, JNJ, NVO)

Boston Scientific (BSX): Saving Itself Through Auctioning Off Pieces

Defensive Stocks Show No Panic Rotation (PEP, KO, BUD, TAP, KFT, CAG, CPB, HRL, MCD, MO, VGR, RAI, PG, CL, MRK, JNJ, NVO)

For Boston Scientific And JNJ, The Stent Stats Get Worse

Interpreting Amgen Sales From J&J’s PROCRIT (AMGN, JNJ)

Johnson & Johnson’s (JNJ) Good Quarter

As Stent Business Falls Apart, Field Gets More Crowded

Medtronic (MDT): The Stent Business Gets Worse

For Boston Scientific (BSX) Stent News Gets More Complex

Media Digest 9/14/2007 Reuters, WSJ, NYTimes, FT, Barron’s

ISIS Scores On J&J Collaboration & Milestones (ISIS, JNJ)

Amgen Set To Run (AMGN, JNJ, BIIB)

Defensive Stock Picks Better Than The Market (September 7, 2007)

Live Nasdaq Composite: Tech Rises on Chip Stock Tailwinds but Software Sinks

TBPN’s John Coogan: “People Can’t Really Complain.” Here’s Why Blue Origin Is Worth $130 Billion.

Palo Alto Just Soared 28% in a Month. Should Investors Take Profits and Rotate Into CrowdStrike or Fortinet?

How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?

How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?

Here's How You Can Retire to Boise, Idaho, at 62 on $900,000 and Never Look Back

TBPN’s John Coogan: “People Can’t Really Complain.” Here’s Why Blue Origin Is Worth $130 Billion.

Palo Alto Just Soared 28% in a Month. Should Investors Take Profits and Rotate Into CrowdStrike or Fortinet?

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

As Doctors Renew Interest In Stents, Boston Scientific (BSX) May Get A Break

Media Digest 11/12/2007 Reuters, WSJ, NYTimes, FT, Barron’s

Defensive Stocks Show Rotation Out of Tech (PEP, KO, BUD, TAP, KFT, CAG, CPB, HRL, MCD, MO, VGR, RAI, PG, CL, MRK, JNJ, NVO)

Boston Scientific (BSX): Saving Itself Through Auctioning Off Pieces

Defensive Stocks Show No Panic Rotation (PEP, KO, BUD, TAP, KFT, CAG, CPB, HRL, MCD, MO, VGR, RAI, PG, CL, MRK, JNJ, NVO)

For Boston Scientific And JNJ, The Stent Stats Get Worse

Interpreting Amgen Sales From J&J’s PROCRIT (AMGN, JNJ)

Johnson & Johnson’s (JNJ) Good Quarter

As Stent Business Falls Apart, Field Gets More Crowded

Medtronic (MDT): The Stent Business Gets Worse

For Boston Scientific (BSX) Stent News Gets More Complex

Media Digest 9/14/2007 Reuters, WSJ, NYTimes, FT, Barron’s

ISIS Scores On J&J Collaboration & Milestones (ISIS, JNJ)

Amgen Set To Run (AMGN, JNJ, BIIB)

Defensive Stock Picks Better Than The Market (September 7, 2007)

Live Nasdaq Composite: Tech Rises on Chip Stock Tailwinds but Software Sinks

TBPN’s John Coogan: “People Can’t Really Complain.” Here’s Why Blue Origin Is Worth $130 Billion.

Palo Alto Just Soared 28% in a Month. Should Investors Take Profits and Rotate Into CrowdStrike or Fortinet?

How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?

Featured Reads

How Large Does Your Portfolio Need to Be to Generate $12,000 a Month?

Here's How You Can Retire to Boise, Idaho, at 62 on $900,000 and Never Look Back